BPC-157 Unknown Long-Term Safety: When to Call the Doctor

HealthRX.com

No long-term human safety data: know the warning signs

Print or save as PDF

At a glance

  • FDA status / Not an FDA-approved drug; no approved product contains BPC-157 in any country FDA searched [1]
  • Adverse-event reports found / 3, all injectable products; causation not established [1]
  • The three reported events / injection-site redness and swelling for 9 days, shortness of breath leading to an emergency room visit, skin and gum darkening that recurred [1]
  • Best human evidence / 3 studies, 30 patients, poor quality, very low certainty (2026 review) [2]
  • Longest described human dosing / 2 weeks (80 mg daily by enema in ulcerative colitis) [1]
  • Animal signals / 28-day studies: aPTT shortened in rats and prolonged in dogs; raised ALT, glucose and triglycerides [1]
  • Routes with no human studies / oral, subcutaneous, nasal and skin [1]

Does BPC-157 have long-term human safety data?

No. BPC-157 is a synthetic peptide of 15 amino acids, described as a fragment of a protein first isolated from human gastric juice, and it is not an FDA-approved drug [1]. FDA identified five small human studies: meeting abstracts, a retrospective chart review, a single-arm pilot and a 2-person pilot [1]. A 2026 systematic review that searched the literature to June 1, 2026 found only 3 studies covering 30 patients in total, all of poor methodological quality, with certainty of evidence rated very low; the reviewers concluded BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [2].

Human dosing in these reports runs from a single procedure to two weeks, for example 80 mg daily by enema for 2 weeks in ulcerative colitis, or 10 mg then 20 mg intravenously on two consecutive days [1].

The three side-effect reports FDA found

FDA searched its adverse-event database through December 4, 2025 and found 3 reports, all involving injectable BPC-157 [1]. One described injection-site redness and swelling that lasted 9 days; that person also used compounded thymosin [1]. One described shortness of breath that led to an emergency room visit, with no other detail recorded [1]. One described widespread skin and gum darkening that recurred when the person was exposed again to a BPC-157 plus TB-500 'research' product [1]. FDA said it cannot tell whether BPC-157 caused any of them [1].

Three reports cannot show how often these events occur or establish that BPC-157 caused them; FDA's adverse-event system accepts reports without verifying them [3].

What the small human studies reported

In the studies FDA reviewed, no serious adverse events were reported, but the studies were short, small and gave limited safety information [1]. In the healthy-volunteer enema studies (meeting abstracts), the most frequent events were headache and flatulence [1]. For a 2005 ulcerative colitis abstract in which 53 people got BPC-157 enema 80 mg or placebo daily for 2 weeks, FDA said the abstract reports no difference in adverse events versus placebo but has too little detail to judge effectiveness [1].

None of the individual studies was built to detect uncommon harm. A retrospective chart review of 17 patients who had BPC-157 injected into the knee (alone or with thymosin beta-4), 16 of whom were contacted by phone, noted no adverse events, with no control group and recalled results [4]. A single-arm pilot in 12 women given a total of 10 mg injected around the bladder wall reported no adverse events [5]. A 2-person intravenous pilot found no measurable change in tested heart, liver, kidney, thyroid or glucose markers over three days and no reported side effects [6].

What the animal studies flagged

FDA cited 28-day intramuscular studies in which BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels [1]. Longer studies and cancer-risk studies were not available [1].

What FDA found, and what it did not

FDA said BPC-157's molecular targets have not been identified, its mechanisms remain poorly understood, and dose-response relationships for the reported protective effects were not established [1]. FDA found no human studies of BPC-157 given by mouth, by subcutaneous injection, as a nasal spray or on the skin, and no human pharmacokinetic data for those routes; after rectal enemas in two early studies the peptide was mostly not detectable in blood [1].

When to call a doctor

All three reports FDA found followed injectable BPC-157 [1].

  • Sudden shortness of breath. Seek emergency care. One report described shortness of breath that led to an emergency room visit after injectable BPC-157, with no other detail recorded [1].
  • New darkening of the skin or gums. Call a clinician. Widespread darkening of skin and gums was reported once, in someone using a BPC-157 plus TB-500 product, and it returned when that person was exposed to the product again [1].
  • An injection site that stays red and swollen. Call a clinician. The reported site reaction stayed red and swollen for 9 days [1].

Two of the three reports involved another peptide as well (compounded thymosin in one, TB-500 in a blended product in the other), so the reports do not isolate BPC-157 [1].

What people on Reddit report

Reader accounts about possible side effects of this peptide, including one person who stopped after a loss of pleasure and one who worried about that same effect before starting.

gG61v · bpc_157

I had no health issues before starting BPC and still got temporary anhedonia. It's always a gamble. I also took it for tendonitis. I took it only a few times before experiencing side effects, so I stopped. My tendonitis did not heal from those few injections.

Reports a temporary loss of pleasure after a few injections, stopped the product, and says the tendon problem did not improve.

Read the source discussion

boki-codes · bpc_157

My main concern is the possible anhedonia side effect, especially since I also deal with mild OCD and intrusive thoughts.

Before starting, worries about the same loss-of-pleasure side effect because of an existing anxiety-related condition.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

Dr Dray on why the long-term safety of BPC peptides is unproven

Dr Dray argues that BPC peptide lacks long-term safety data in people, pointing to only a handful of small, uncontrolled human studies with fewer than thirty participants in total. She warns that animal and laboratory findings do not establish a safe dose or rule out long-term risks. In her view, products bought from overseas sites or sold as research chemicals may contain impurities, wrong concentrations, or contamination, and the recent enforcement policy expands access without proving safety or effectiveness. She advises discussing risks with a qualified clinician who can monitor for side effects, and cautions against delaying appropriate care for an injury or other condition.

Who is speaking?

Dr Dray. Dermatologist, as described in the video description Background

Episode notes and full video

What to bring to the appointment

When seeking care for a possible reaction, bring the product name and whether it is the free base or the acetate salt (FDA treats these as different bulk substances), the route, the dose in milligrams, the dates of use, and details of any other peptides used at the same time [1].

What FDA's stated concerns are

FDA's concerns about compounded BPC-157 are that it 'may pose risk for immunogenicity for certain routes of administration' and may have problems with peptide-related impurities and characterization of the active ingredient [7]. FDA also said it 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [7]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [8][9].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. According to the article, what are all three FDA adverse-event reports about BPC-157 linked to?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Frequently asked questions

How long were people followed in the BPC-157 studies?
The longest described exposure is 2 weeks, at 80 mg daily by enema in ulcerative colitis [1]. Other reports are single procedures: 10 mg injected around the bladder wall once, and 10 mg then 20 mg intravenously on two consecutive days [5][6].
What side effects have actually been reported with BPC-157?
FDA's database search through December 4, 2025 found 3 reports: injection-site redness and swelling for 9 days, shortness of breath leading to an emergency room visit, and widespread skin and gum darkening that recurred on re-exposure. All involved injectable products and FDA could not tell whether BPC-157 caused them [1].
What should I do if I get short of breath after using BPC-157?
Seek emergency care. One report to FDA described shortness of breath after injectable BPC-157 that led to an emergency room visit, with no other detail recorded [1].
Can BPC-157 cause cancer?
Whether BPC-157 affects cancer risk is unknown. FDA noted that longer animal studies and cancer-risk studies were not available [1].
Have blood markers been checked in people given BPC-157?
In a two-person intravenous pilot, researchers found no measurable change in the tested heart, liver, kidney, thyroid or glucose markers over three days; that small, short study cannot establish long-term safety [6].
Is compounded BPC-157 quality-checked?
Compounded drugs are not FDA-approved and FDA does not review their safety, effectiveness or quality before marketing [8][9]. FDA's stated concerns about BPC-157 include peptide-related impurities, characterization of the active ingredient and possible immunogenicity for certain routes [7].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

How long does BPC-157 last in your system?

No duration is established for how long BPC-157 stays in the body. In two early rectal enema studies the peptide was mostly not detectable in blood, and there is no human pharmacokinetic data for oral, subcutaneous, nasal or skin routes.

How long should you actually run BPC 157?

No safe duration has been established. The longest described human dosing is 2 weeks, at 80 mg daily by enema in ulcerative colitis, and there is no long-term human safety data. The longest animal studies lasted 28 days.

References

Show all 11 referencesHide references
  1. U.S. Food and Drug Administration.
  2. Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92(3).
  3. FDA Adverse Event Monitoring System (AEMS) Public Dashboard | FDA.
  4. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13.
  5. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17.
  6. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24.
  7. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  8. U.S. Department of Health and Human Services. Notice of draft enforcement-discretion policy for compounding with certain peptides. Federal Register public inspection document 2026-22192. HHS peptide enforcement-discretion notice
  9. U.S. Food and Drug Administration.
  10. Reddit participants. BPC-157 for long-term Achilles pain (with Hashimoto's) — anyone with similar experience? (r/bpc_157). Accessed 2026-11-11.
  11. Dr Dray. BPC-157, TB-500 & Peptides for Anti-Aging: Are They Safe?. Accessed 2026-11-11.
Evidence overview for BPC-157 Unknown Long-Term Safety: When to Call the Doctor